Aurinia Pharmaceuticals Inc. AUPH 深 滬
已收盤 08-07 16:00:00 美东时间
15.85
-0.280
-1.74%
華盛通- 最 高16.59
- 今 開16.26
- 成交量 154.52万股
- 最 低 15.60
- 昨 收 16.13
- 總市值 20.38亿
- 52周最高 19.25
- 市盈率 靜 7.65
- 換手率 0.00%
- 52周最低 10.34
- 委 比 10.32%
- 總股本 1.29亿
- 歷史最高 33.972
- 量 比 1.06
- 振 幅 6.14%
- 歷史最低 1.41
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
08-06 20:41
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $83.220 mil...
08-06 20:40
Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
08-04 00:32
Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
06-13 00:34
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death
Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in
06-04 19:13
Tang Capital takes 10% stake in Aurinia Pharma
Tang Capital Management Tuesday said that it acquired 206,005 common shares of Aurinia Pharmaceuticals (AUPH) at a price of $15.28 per share for an aggregate purchase price of $3.1M. As a result of th...
06-03 15:54
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
